Morning Versus Bedtime Dosing of Antihypertensive Medication

Hypertension Clinical Trial

Official title:

Morning Versus Bedtime Dosing of Antihypertensive Medication in Grade 1 Day-night Hypertension: a Multicenter Randomized Controlled Trial (Dosing-Time Trial)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05089448
• Other study ID #: Dosing-Time Trial20210118
• Status: Recruiting
• Phase: Phase 4
• Start date: January 28, 2021
• Est. completion date: January 31, 2023

Study information

• Verified date: October 2021
• Source: Shanghai Institute of Hypertension
• Contact: Li Yan, Professor
• Phone: 021-64370045
• Email: liyanshcn[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous studies have shown that elevated nighttime blood pressure (BP) was more closely associated with cardiovascular mortality and morbidity than daytime and clinic BPs. With increasingly advanced technology, not only 24-hour ambulatory but also home BP monitors can be used to evaluate nighttime BP. The validation study of the Omron HEM 9601T showed that the wrist-type home BP monitor could be a suitable and reliable tool for the diagnosis and management of nocturnal hypertension. However, up to now, there is no data on home nighttime BP in Chinese patients and it is unclear if different dosing time would reduce ambulatory and home nighttime BPs differently. The investigators therefore designed a multicenter randomized clinical trial to compare between morning dosing and bedtime dosing of antihypertensive medications in the difference in nighttime, daytime and the 24-h BP reductions evaluated by both ambulatory and home BP monitoring, and in target organ protections.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: January 31, 2023
• Est. primary completion date: January 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Male or female patients aged 18-70 years old;

2. Never treated for hypertension or stopped using antihypertensive drugs for at least 2 weeks;

3. In the two screenings,the clinical systolic BP should be in the range of 140-159 mmHg, the diastolic BP < 100 mmHg;

4. The average 24-hour systolic BP =130mmHg, daytime systolic BP = 135 mmHg, and nighttime systolic BP = 120 mmHg;

5. The average of bilateral brachial-ankle pulse wave velocity =14m/s;

6. Be willing to participate in the trial, sign the informed consent form, and be able to visit doctors by himself or herself.

Exclusion Criteria:

1. Secondary hypertension;

2. Concomitant obstructive sleep apnea (STOP-BANG score = 5), insomnia, Parkinson's syndrome, or nocturnal polyuria and other diseases that affect nighttime BP;

3. Need to work at night;

4. Ambulatory BP monitoring was invalid (<70% valid readings, or <20 daytime readings or <7 nighttime readings);

5. Concomitant diseases that need taking medications influencing BP;

6. Coronary heart disease, myocardial infarction or stroke within recent 6 months;

7. Atrial fibrillation or frequent arrhythmia;

8. Abnormal liver function exemplified as an increased alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) over the double of the upper limit of normal range; abnormal renal function exemplified as a serum creatinine =176 µmol/L; and plasma potassium =5.5 mmol/L or =3.5mmol/L;

9. Pregnant or lactating women;

10. Contraindications of angiotensin II receptor blocker or calcium channel blocker;

11. Other concomitant diseases which are considered not suitable to participate in the trial, such as thyroid diseases, acute infectious diseases, chronic mental diseases, tumor, etc.

Related Conditions & MeSH terms

• Blood Pressure
• Drug Use
• Hypertension

Intervention

Drug:
• Alisartan, Amlodipine besylate
Drugs will be taken once daily at 6:00-10:00.
• Alisartan, Amlodipine besylate
Drugs will be taken once daily at 20:00-24:00.

Locations

Country	Name	City	State
China	Ruijin Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Yan Li

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Nighttime systolic BP reduction in mmHg	The difference between the morning and bedtime dosing groups in nighttime systolic BP reduction in mmHg measured by the ambulatory BP monitoring after the treatment for 24 weeks	24 weeks
Secondary	Daytime systolic BP reduction in mmHg, 24-Hour systolic BP reduction in mmHg, Home systolic BP reduction in mmHg	The difference between the morning and bedtime dosing groups in the daytime and 24-hour systolic BPs reduction in mmHg measured by the ambulatory BP monitoring and home systolic BP reduction in mmHg after treatment for 24 weeks	24 weeks
Secondary	Brachial-ankle pulse wave velocity reduction in cm per second	The difference between the morning and bedtime dosing groups in reduction of brachial-ankle pulse wave velocity after treatment for 12 and 24 weeks	12 and 24 weeks
Secondary	Ambulatory night-to-day BP ratio change in percent; proportions of non-dippers in percent, morning systolic blood pressure in mmHg,	The difference between the morning and bedtime dosing groups in change of Ambulatory night-to-day BP ratio change in percent; proportions of non-dippers in percent, and morning systolic blood pressure in mmHg after treatment for 8 and 24 weeks.	8 weeks and 24 weeks
Secondary	Urinary albumine-to-creatinine ratio change in mg/mmol	The difference between the morning and bedtime dosing groups in change of microalbumine-to-creatinine ratio in random urine samples after treatment for 12 weeks and 24 weeks	12 weeks and 24 weeks
Secondary	change in prevalence of left ventricular hypertrophy defined based on electrocardiogram	The difference between the morning and bedtime dosing groups in the change in prevalence (percentage) of left ventricular hypertrophy defined based on Cornell product and Sokolow-Lyon index in electrocardiogram after treatment for 12 weeks and 24 weeks	12 weeks and 24 weeks
Secondary	change in prevalence of left ventricular hypertrophy defined based on echocardiography	prevalence (percentage) of left ventricular hypertrophy defined based on left ventricular mass index assessed by echocardiography after treatment for 24 weeks	24 weeks
Secondary	Serum uric acid in umol/L	The difference between the morning and bedtime dosing groups in serum uric acid in umol/L after treatment for 24 weeks	24 weeks
Secondary	The difference in daytime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks	The difference in daytime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks	24 weeks
Secondary	The difference in nighttime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks	The difference in nighttime systolic and diastolic BPs between the ambulatory and home BP monitoring at baseline and after treatment for 24 weeks	24 weeks